APA (7th ed.) Citation

S, A., A, B., A, K., R, S., R, M., B, B., . . . A, D. (2026). CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer. British journal of cancer, 135(2), 303. https://doi.org/10.1038/s41416-026-03388-z

Chicago Style (17th ed.) Citation

S, Ahmad, et al. "CDKN1B Inactivation Impacts ER Signaling and Drives Resistance to Endocrine Therapy in Breast Cancer." British Journal of Cancer 135, no. 2 (2026): 303. https://doi.org/10.1038/s41416-026-03388-z.

MLA (9th ed.) Citation

S, Ahmad, et al. "CDKN1B Inactivation Impacts ER Signaling and Drives Resistance to Endocrine Therapy in Breast Cancer." British Journal of Cancer, vol. 135, no. 2, 2026, p. 303, https://doi.org/10.1038/s41416-026-03388-z.